Substantially Improving the Cure Rate of High-risk BRCA1-like Breast Cancer
Status:
Recruiting
Trial end date:
2029-12-01
Target enrollment:
Participant gender:
Summary
Investigator-initiated, international, multicentre, randomized, open-label, (neo)adjuvant
phase III study in target population (stage III, HER2-negative, BRCA1-like breast cancer
patients) comparing optimized standard-dose chemotherapy with intensified, alkylating
chemotherapy with stem cell rescue.